Processing, please wait...

Dr Ahmet Ali ALTINTAS

Plastic Surgeon
Germany

Prof. Dr. med. A.A. Altintas, M.Sc ( Germany)
 

Altintas (13.05.1983) is Professor for Plastic surgery in Germany. He was graduated from Ruhr University Bochum, Germany. His Doctoral thesis was about Tendon Transfer for Radial nerve Palsy at the BG Trauma Center Ludwigshafen, Department of Plastic and Hand Surgery at the Ruperto Carola University of Heidelberg, Heidelberg, Germany. He has a Master’s degree (M.Sc.) in Public health from Ruperto Carola University in Heidelberg. His surgical career started at the general surgery at the University Heidelberg, followed by German Center of Trauma Surgery at the Hannover Medical School. He worked at the Department of Plastic Surgery, Burn and Hand Surgery Center, Cologne Merheim, Germany. Altintas hold board certification for Plastic and Aesthetic Surgery. He was Senior Consultant at the Department of Plastic and Hand Surgery at the University of Essen , Essen, Germany, and since 2011, he has been an Vice Director of the Department of Plastic Surgery Diakonische Kliniken Hannover. Dr. Altintas is a member of the editorial board in numerous Journals in Plastic and Aesthetic Surgery such as Advanced in Wound care ( impact Factor 5.2) He presented more than 80 papers at national and international scientific meetings. He has published more than 50 peer reviewed papers in scientific journals and various book chapters. 

His research focuses on Aesthetic Surgery, Reconstructive plastic procedures and wound healing.

read more
add item add Ahmet Ali ALTINTAS

Ahmet Ali ALTINTAS's publications (10)

Risk of secondary progressive multiple sclerosis: A longitudinal study.

01, 2020

The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. read more

Multiple sclerosis (Houndmills, Basingstoke, England)

CD3CD56 NK cells display an inflammatory profile in RR-MS patients.

12, 2019

Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status. read more

Immunology letters

Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.

Nov, 2019

Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed. read more

Multiple sclerosis and related disorders
Load more  

Ahmet Ali ALTINTAS's learned societies (1)